For instance, a clinical trial completed in April 2022 by researchers at Mansoura University (Egypt) investigated the association between lncRNA H19 and IGF1 receptor gene expressions in patients with HCC and T2D to uncover the underlying pathophysiological link between HCC and T2D, which may become a therapeutic target for both diseases (NCT04767750). Here, H19 is linked to hepatocellular carcinoma.